221 related articles for article (PubMed ID: 28857052)
1. Antiarrhythmic drug usage and prostate cancer: a population-based cohort study.
Kao LT; Huang CC; Lin HC; Huang CY
Asian J Androl; 2018; 20(1):37-42. PubMed ID: 28857052
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial.
Kaapu KJ; Murtola TJ; Määttänen L; Talala K; Taari K; Tammela TL; Auvinen A
Cancer Causes Control; 2016 Feb; 27(2):157-64. PubMed ID: 26573846
[TBL] [Abstract][Full Text] [Related]
3. Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population-based case-control study.
Kaapu KJ; Ahti J; Tammela TL; Auvinen A; Murtola TJ
Int J Cancer; 2015 Sep; 137(5):1187-95. PubMed ID: 25656312
[TBL] [Abstract][Full Text] [Related]
4. Rate-control treatment and mortality in atrial fibrillation.
Chao TF; Liu CJ; Tuan TC; Chen SJ; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Chen TJ; Chiang CE; Chen SA
Circulation; 2015 Oct; 132(17):1604-12. PubMed ID: 26384160
[TBL] [Abstract][Full Text] [Related]
5. Preadmission Use of Calcium Channel Blocking Agents Is Associated With Improved Outcomes in Patients With Sepsis: A Population-Based Propensity Score-Matched Cohort Study.
Lee CC; Lee MG; Lee WC; Lai CC; Chao CC; Hsu WH; Chang SS; Lee M
Crit Care Med; 2017 Sep; 45(9):1500-1508. PubMed ID: 28658023
[TBL] [Abstract][Full Text] [Related]
6. Calcium Channel Blocker Use and the Risk for Prostate Cancer: A Population-Based Nested Case-Control Study.
Rotshild V; Azoulay L; Feldhamer I; Perlman A; Muszkat M; Matok I
Pharmacotherapy; 2019 Jun; 39(6):690-696. PubMed ID: 30917404
[TBL] [Abstract][Full Text] [Related]
7. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA
Eur Urol; 2014 Mar; 65(3):635-41. PubMed ID: 23351721
[TBL] [Abstract][Full Text] [Related]
8. Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD.
Huang YL; Lai CC; Wang YH; Wang CY; Wang JY; Wang HC; Yu CJ; Chen L
Int J Chron Obstruct Pulmon Dis; 2017; 12():2987-2996. PubMed ID: 29066880
[TBL] [Abstract][Full Text] [Related]
9. Calcium-channel blockers and risk of cancer.
Jick H; Jick S; Derby LE; Vasilakis C; Myers MW; Meier CR
Lancet; 1997 Feb; 349(9051):525-8. PubMed ID: 9048789
[TBL] [Abstract][Full Text] [Related]
10. No association between calcium channel blocker use and confirmed bleeding peptic ulcer disease.
Smalley WE; Ray WA; Daugherty JR; Griffin MR
Am J Epidemiol; 1998 Aug; 148(4):350-4. PubMed ID: 9717878
[TBL] [Abstract][Full Text] [Related]
11. Inverse association between prostate cancer and the use of calcium channel blockers.
Debes JD; Roberts RO; Jacobson DJ; Girman CJ; Lieber MM; Tindall DJ; Jacobsen SJ
Cancer Epidemiol Biomarkers Prev; 2004 Feb; 13(2):255-9. PubMed ID: 14973089
[TBL] [Abstract][Full Text] [Related]
12. The relationship between antihypertensive combination therapies comprising diuretics and/or beta-blockers and the risk of new-onset diabetes: a retrospective longitudinal cohort study.
Liou YS; Ma T; Tien L; Lin CM; Jong GP
Hypertens Res; 2009 Jun; 32(6):496-9. PubMed ID: 19390541
[TBL] [Abstract][Full Text] [Related]
13. Statin, calcium channel blocker and Beta blocker therapy may decrease the incidence of tuberculosis infection in elderly Taiwanese patients with type 2 diabetes.
Lee MY; Lin KD; Hsu WH; Chang HL; Yang YH; Hsiao PJ; Shin SJ
Int J Mol Sci; 2015 May; 16(5):11369-84. PubMed ID: 25993300
[TBL] [Abstract][Full Text] [Related]
14. A cohort study of digoxin exposure and mortality in men with prostate cancer.
Flahavan EM; Sharp L; Bennett K; Barron TI
BJU Int; 2014 Feb; 113(2):236-45. PubMed ID: 23937513
[TBL] [Abstract][Full Text] [Related]
15. Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer.
Kaapu KJ; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
Br J Cancer; 2016 Nov; 115(11):1289-1295. PubMed ID: 27755533
[TBL] [Abstract][Full Text] [Related]
16. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA; Håheim LL
Prostate; 2013 Feb; 73(3):250-60. PubMed ID: 22821802
[TBL] [Abstract][Full Text] [Related]
17. Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study.
Chiang IN; Huang CY; Pu YS; Chang CH; Muo CH; Chung CJ; Wang RY; Young TH
BMJ Open; 2017 Feb; 7(2):e012950. PubMed ID: 28246133
[TBL] [Abstract][Full Text] [Related]
18. The association between beta-blockers use and prostate cancer mortality: A mini systematic review and meta-analysis.
Uleri A; Baboudjian M; Tedde A; Rajwa P; Pradere B; Gallioli A; Breda A; Ploussard G
Prostate; 2024 Jan; 84(1):3-7. PubMed ID: 37710384
[TBL] [Abstract][Full Text] [Related]
19. Digoxin lowers the incidence of prostate cancer: A nationwide population-based study.
Lin TP; Fan YH; Chen YC; Huang WJS
J Chin Med Assoc; 2020 Apr; 83(4):377-381. PubMed ID: 32132383
[TBL] [Abstract][Full Text] [Related]
20. Long-term Effects of Antihypertensive Drug Use and New-onset Osteoporotic Fracture in Elderly Patients: A Population-based Longitudinal Cohort Study.
Chen HY; Ma KY; Hsieh PL; Liou YS; Jong GP
Chin Med J (Engl); 2016 Dec; 129(24):2907-2912. PubMed ID: 27958221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
